Answers are grounded in this paper and cite their sources.
This is the first GWA study to find SNPs affecting PFS in mCRC patients treated with CAPOX-B, either with or without cetuximab. Rs885036 is a potential predictive marker for cetuximab efficacy. These markers need to be validated in independent treatment cohorts.
No takes yet. Share an insight, caveat, or question.
Pander et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: